Atara Biotherapeutics (ATRA) Change in Receivables (2020 - 2026)
Atara Biotherapeutics (ATRA) posted Change in Receivables of -$1.3 million for Q1 2026, down 89.85% on a QoQ basis from -$660000.0 in Q4 2025, and down 116.95% year-over-year from $7.4 million in Q1 2025.
Atara Biotherapeutics (ATRA) Change in Receivables (2020 - 2026) Analysis & Trends
Atara Biotherapeutics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$1.3 million for Q1 2026.
- Quarterly Change in Receivables fell 116.95% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (up 67.08% YoY) and the FY2025 annual result came in at -$229000.0, up 99.3% from the prior year.
- Change in Receivables was -$1.3 million for Q1 2026 at Atara Biotherapeutics, down from -$660000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $40.0 million in Q4 2022 and bottomed at -$39.8 million in Q1 2023.
- A 5-year average of -$58000.0 and a median of -$318000.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 3953.96% — and 2024, when it plunged 30474.55%.
- Atara Biotherapeutics' Change in Receivables stood at $40.0 million in 2022, then slipped by 15.08% to $33.9 million in 2023, then tumbled by 99.57% to $147000.0 in 2024, then sank by 548.98% to -$660000.0 in 2025, then sank by 89.85% to -$1.3 million in 2026.
- Business Quant data shows ATRA's Change in Receivables at -$1.3 million in Q1 2026, -$660000.0 in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.25 Mn |
| Mar 31, 2026 | -1.25 Mn |
| Dec 31, 2025 | -660,000.00 |
| Dec 31, 2025 | -660,000.00 |
| Sep 30, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | -8.88 Mn |
| Jun 30, 2025 | -8.88 Mn |
| Mar 31, 2025 | 7.39 Mn |
| Mar 31, 2025 | 7.39 Mn |
| Dec 31, 2024 | 147,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Sep 30, 2024 | -1.09 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -33.41 Mn |
| Jun 30, 2024 | -33.41 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 33.95 Mn |
| Dec 31, 2023 | 33.95 Mn |